REGENXBIO - Stock Price History | RGNX
Historical daily share price chart and data for REGENXBIO since 2023 adjusted for splits. The latest closing stock price for REGENXBIO as of February 03, 2023 is 23.75.
- The all-time high REGENXBIO stock closing price was 82.15 on July 10, 2018.
- The REGENXBIO 52-week high stock price is 35.73, which is 50.4% above the current share price.
- The REGENXBIO 52-week low stock price is 18.69, which is 21.3% below the current share price.
- The average REGENXBIO stock price for the last 52 weeks is 25.89.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
REGENXBIO Historical Annual Stock Price Data |
Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
2022 |
26.2713 |
34.3100 |
35.0400 |
19.3500 |
22.6800 |
-30.64% |
2021 |
37.0514 |
44.9700 |
49.9500 |
29.0900 |
32.7000 |
-27.91% |
2020 |
36.5798 |
38.9900 |
54.2000 |
21.5000 |
45.3600 |
10.72% |
2019 |
44.7959 |
43.3300 |
62.4500 |
31.8400 |
40.9700 |
-2.34% |
2018 |
52.0580 |
34.7500 |
82.1500 |
24.0500 |
41.9500 |
26.17% |
2017 |
22.8349 |
18.5000 |
34.6000 |
16.7000 |
33.2500 |
79.25% |
2016 |
13.4967 |
17.0000 |
24.0000 |
7.3200 |
18.5500 |
11.75% |
2015 |
20.6147 |
30.4500 |
30.7000 |
14.1500 |
16.6000 |
0.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$1.028B |
$0.470B |
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|